Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | C1R | P00736 | 3/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921298 | 0.76 | ADORA2A (0.44) | ELANEF2CFDC1RALDH1A1 | |
| SCHEMBL30042357 | 0.75 | KDM4E (0.45) | ELANEF2CFDC1RALDH1A1 | |
| SCHEMBL1266435 | 0.75 | ADORA1 (0.50) | F2CFDKDM4E | |
| SCHEMBL30499843 | 0.73 | ALDH1A1 (0.41) | MAT2AALDH1A1GAAHPGDKDM4E | |
| SCHEMBL21145512 | 0.70 | ADORA2A (0.57) | MAT2AALDH1A1GAAKDM4E | |
| SCHEMBL30611217 | 0.70 | ALDH1A1 (0.41) | ALDH1A1GAAHPGDKDM4E | |
| SCHEMBL29110299 | 0.70 | ALDH1A1 (0.41) | ALDH1A1GAAHPGDKDM4E | |
| SCHEMBL29569871 | 0.69 | MAT2A (0.49) | MAT2AALDH1A1GAAHPGDKDM4E | |
| SCHEMBL30549011 | 0.67 | HPGD (0.40) | ALDH1A1GAAHPGD | |
| SCHEMBL30039796 | 0.67 | HPGD (0.40) | ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PEAKDALE MOLECULAR LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137558-A1 | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products | PNPO, CYP4B1, PDXK | ELANE 4732/4885F2 1287/4885CFD 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.